BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Maryland Psychiatric Society - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Maryland Psychiatric Society
X-ORIGINAL-URL:https://mdpsych.org
X-WR-CALDESC:Events for Maryland Psychiatric Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210917T123000
DTEND;TZID=America/New_York:20210917T133000
DTSTAMP:20210902T151612Z
CREATED:20210902T144238Z
LAST-MODIFIED:20210902T151612Z
UID:4742-1631881800-1631885400@mdpsych.org
SUMMARY:Free Recovery Month Webinar: Benzodiazepine and prescription stimulant use in youth — What’s the impact on SUD and its treatment?
DESCRIPTION:Please join the Maryland Addiction Consultation Service (MACS) and the Maryland Behavioral Health Integration in Pediatric Primary Care (BHIPP) for a webinar focused on Benzodiazepine and Prescription Stimulant Use in Youth. The session will feature a presentation by MACS consultant Marc Fishman\, MD\, addiction psychiatrist\, Medical Director of Maryland Treatment Centers\, and a member of the Psychiatry faculty of the Johns Hopkins University School of Medicine. \nTo combat the opioid use disorder (OUD) epidemic\, the U.S. Department of Health and Human Services has expanded access to medication for opioid disorder. As of January 2021\, there are fewer requirements for physicians to receive their waiver to prescribe buprenorphine to treat OUD. Following the session\, MACS staff will provide technical support to providers interested in applying for their waiver. \nFree CME/CPE/CEU credit available for participation!\n*Certificates will only be awarded to participants that attend for the entire duration and complete the post event evaluation form. \nLearning Objectives\nBy the end of the session\, participants will be able to:\n1.) Identify therapeutic benefits\, risks and side effects associated with use of benzodiazepines and prescription stimulants\n2.) Identify vulnerabilities and risks of misuse of benzodiazepines and prescription stimulants in youth\, including progression to use disorder\n3.) Identify approaches to treatment of SUD and psychiatric co-morbidities in youth with benzodiazepine and prescription stimulant misuse \nCME/CPE/CEU Credit for Participation:\nApplication for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending. Maryland Behavioral Health Integrated Pediatric Primary Care Program (BHIPP) of the University of Maryland School of Medicine\, Department of Psychiatry is authorized as a sponsor of Continuing Education Units. BHIPP maintains responsibility for this program. \nUniversal Activity Number (UAN): 0025-9999-21-098-L04-P\nCPE Credit: 1.0 Contact Hours (0.1 CEU) \nTechnical Requirements: https://help.webex.com/en-us/nki3xrq/Webex-Meetings-Suite-System-Requirements \nAbout the Presenter(s):\nMarc Fishman\, MD\, is an addiction psychiatrist\, Medical Director of Maryland Treatment Centers\, and a member of the Psychiatry faculty of the Johns Hopkins University School of Medicine. Dr Fishman leads Maryland Treatment Centers\, a regional behavioral health care provider\, which includes Mountain Manor Treatment Centers in Baltimore and Emmitsburg as well as several other inpatient and outpatient programs. In that role he has been involved in development and implementation of innovative programming in addiction and co-occurring disorder treatment. His clinical specialties include treatment of drug-involved and dual-diagnosis youth\, opioid addiction in adolescents and adults\, and addiction with co-occurring psychiatric disorders. His research work has focused on medication treatment for SUDs as well as\, models of care and treatment outcomes in youth\, in particular opioid addiction. He has been a president of the MD Society of Addiction Medicine\, and is currently a member of its Board.
URL:https://mdpsych.org/meetings/bhipp-resilience-break-benzodiazepine-and-prescription-stimulant-use-in-youth-whats-the-impact-on-sud-and-its-treatment/
LOCATION:Remote Participation Only
END:VEVENT
END:VCALENDAR